PRF Technologies FDA clears IND for OcuRing-K Phase II trial
PRF Technologies said the FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery. Patient enrollment is expected in the second half of 2026.
FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery with patient enrollment expected in the second half of 2026PRF-110 matched an approved, commercially available benchmark on 72-hour analgesic activity using a ropivacaine-only, NSAID-free formulation…